{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:19:26Z","timestamp":1789989566443,"version":"4.0.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13792-y","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T17:02:04Z","timestamp":1744822924000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of lenalidomide consolidation on health-related quality of life in chronic lymphocytic leukemia: ancillary study of the phase III CLL6-RESIDUUM trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Stephane Kroudia","family":"Wasse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine Tienhan","family":"Dabakuyo-Yonli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Cymbalista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Maynadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se","family":"Aurran-Schleinitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"13792_CR1","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","volume":"108","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108:3458\u201364.","journal-title":"Blood"},{"key":"13792_CR2","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","volume":"26","author":"PH Wiernik","year":"2008","unstructured":"Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26:4952\u20137.","journal-title":"J Clin Oncol"},{"key":"13792_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa041668","volume":"352","author":"A List","year":"2005","unstructured":"List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549\u201357.","journal-title":"N Engl J Med"},{"key":"13792_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S1470-2045(06)70723-9","volume":"7","author":"A Chanan-Khan","year":"2006","unstructured":"Chanan-Khan A, Porter CW. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol. 2006;7:480\u20138.","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"13792_CR5","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1182\/blood-2023-181595","volume":"142","author":"T Aurran-Schleinitz","year":"2023","unstructured":"Aurran-Schleinitz T, Mulligan SP, Letestu R, Bene MC, Cull G, Vilque JP, et al. Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO). Blood. 2023;142(Supplement 1):4641.","journal-title":"Blood."},{"issue":"11","key":"13792_CR6","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","volume":"111","author":"A Ferrajoli","year":"2008","unstructured":"Ferrajoli A, Lee BN, Schlette EJ, O\u2019Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111(11):5291\u20137.","journal-title":"Blood"},{"issue":"12","key":"13792_CR7","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446\u201356.","journal-title":"Blood."},{"issue":"6","key":"13792_CR8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1600-0609.2004.00233.x","volume":"72","author":"B Holzner","year":"2004","unstructured":"Holzner B, Kemmler G, Kopp M, Nguyen-Van-Tam D, Sperner-Unterweger B, Greil R. Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr. Eur J Haematol. 2004;72(6):381\u20139.","journal-title":"Eur J Haematol"},{"key":"13792_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139\u201344.","journal-title":"J Clin Oncol"},{"key":"13792_CR10","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.ejca.2008.05.008","volume":"44","author":"K Cocks","year":"2008","unstructured":"Cocks K, King MT, Velikova G, et al. Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer. 2008;44:1793\u20138.","journal-title":"Eur J Cancer"},{"key":"13792_CR11","unstructured":"Aurran T, Mulligan S, B\u00e9n\u00e9 MC, et al. Lenalidomide consolidation improves progression-free survival in patients with Chronic Lymphocytic Leukemia following initial FCR chemotherapy - Final analysis of CLL6 residuum study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO). Available online: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper181595.html. Accessed 22 Feb 2025."},{"issue":"22","key":"13792_CR12","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1182\/blood.V128.22.2053.2053","volume":"128","author":"D Gottlieb","year":"2016","unstructured":"Gottlieb D, Aurran T, Tam CS, et al. Interim analysis of lenalidomide consolidation on minimal residual disease in patients with chronic lymphocytic leukemia following initial FCR chemotherapy - CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO). Blood. 2016;128(22):2053.","journal-title":"Blood"},{"issue":"S1","key":"13792_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/01.HS9.0000559784.51441.da","volume":"3","author":"D Gottlieb","year":"2019","unstructured":"Gottlieb D, Aurran-Schleinitz T, Mulligan S, et al. A randomised joint Australasian (ALLG) and French (FILO) study of lenalidomide consolidation in patients with residual CLL after front-line treatment with FC\/FCR (the CLL6 trial). Hemasphere. 2019;3(S1):129.","journal-title":"Hemasphere"},{"issue":"6","key":"13792_CR14","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.3324\/haematol.2019.222299","volume":"105","author":"LK Nielsen","year":"2020","unstructured":"Nielsen LK, Stege C, Lissenberg-Witte B, van der Holt B, et al. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. Haematologica. 2020;105(6):1650\u20139.","journal-title":"Haematologica"},{"issue":"6","key":"13792_CR15","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.1016\/S2352-3026(22)00103-X","volume":"9","author":"MA Dimopoulos","year":"2022","unstructured":"Dimopoulos MA, Richardson PG, Bahlis NJ, et al. ELOQUENT-1 investigators. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2022;9(6):e403\u201314.","journal-title":"Lancet Haematol."},{"issue":"1","key":"13792_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/bjh.16300","volume":"189","author":"C Thieblemont","year":"2020","unstructured":"Thieblemont C, Howlett S, Casasnovas RO, et al. Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. Br J Haematol. 2020;189(1):84\u201396.","journal-title":"Br J Haematol"},{"issue":"9","key":"13792_CR17","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1080\/03007995.2020.1784120","volume":"36","author":"C Waweru","year":"2020","unstructured":"Waweru C, Kaur S, Sharma S, Mishra N. Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents. Curr Med Res Opin. 2020;36(9):1481\u201395.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"13792_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.clml.2021.09.008","volume":"22","author":"AV Danilov","year":"2022","unstructured":"Danilov AV, Yimer HA, Boxer MA, et al. Improvements in health-related quality of life and symptoms in patients with previously untreated chronic lymphocytic leukemia: Final results from the phase II GIBB study of the combination of obinutuzumab and bendamustine. Clin Lymphoma Myeloma Leuk. 2022;22(2):121\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13792-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13792-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13792-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T17:02:07Z","timestamp":1744822927000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13792-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13792"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13792-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the French National Competent authority (Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament, Reference: 131618A-11) and an Ethics Committee (CPP de Sud M\u00e9diterran\u00e9e I, Reference: 14 05). The study was performed according to the principles of the Declaration of Helsinki. All patients provided written informed consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"712"}}